WIXOM, Mich., April 15, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, reported today that it has added Alvin L. Crumbliss, Ph.D to its Scientific Advisory Board (SAB). Rockwell's SAB currently advises the Company on clinical development for its investigational, continuous iron-maintenance drug SFP, currently in Phase III clinical studies, as well as other potential indications.
Dr. Alvin L. Crumbliss is Bishop-MacDermott Family Professor of Chemistry at Duke University, the Dean of the Faculty of Arts & Sciences and the Dean of Trinity College, Duke University. Dr. Crumbliss is an internationally recognized expert in iron chemistry, having authored over 200 peer reviewed journal articles and book chapters in his distinguished career. He has served as a Councilor to American Chemical Society since 1998, and is the Associate Editor of the journal BioMetals. In addition, Dr. Crumbliss currently serves on the Editorial Advisory Boards of the journal Metallomics and the Journal of Inorganic Biochemistry.
Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, "We are especially pleased to have Dr. Crumbliss join our SAB. Al brings exceptional expertise in the field of iron chemistry to the Company and that will help Rockwell exploit the full potential of SFP for the benefit of iron deficient patients with chronic kidney disease, inflammation, cancer, gastrointestinal diseases, and those dependent of parenteral nutrition."
Dr. Alvin L. Crumbliss, Professor of Chemistry at Duke University, Dean of the Faculty of Arts & Sciences and Dean of Trinity College, Duke University commented, "My thanks to Mr. Chioini and the Rockwell team for bringing me onto their Scientific Advisory Board. My goal will be to provide expertise to Rockwell that will be helpful in enabling the development of novel therapies to benefit iron deficient patients with chronic diseases."
About Rockwell Medical:
Rockwell Medical is a fully-integrated biopharmaceutical company offering innovative products and services initially targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia. An established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad, Rockwell provides products that are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Dialysis is a process that duplicates kidney function for patients who suffer from ESRD. There are approximately 400,000 ESRD patients in the United States. World-wide there are approximately 2 million ESRD patients, growing at an annual rate of 5-6 percent.
The Company is currently developing unique, proprietary renal drug therapies for iron treatment. These exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are designed to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of SFP for indications outside of hemodialysis. Please visit for more information.
The Rockwell Medical Technologies, Inc. logo is available at
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan", "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical's SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
CONTACT: Carl Belczynski, VP Investor Relations Rockwell Medical (248) 960-9009 Brian Korb, VP The Trout Group LLC (646) 378-2923